TY - JOUR
T1 - ElectroConvulsive therapy Cognitive Assessment (ECCA) tool
T2 - A new instrument to monitor cognitive function in patients undergoing ECT
AU - The National Network of Depression Centers ECT Task Group
AU - Hermida, Adriana P.
AU - Goldstein, Felicia C.
AU - Loring, David W.
AU - McClintock, Shawn M.
AU - Weiner, Richard D.
AU - Reti, Irving M.
AU - Umair Janjua, A.
AU - Ye, Zixun
AU - Peng, Limin
AU - Tang, Yi lang
AU - Galendez, Gail C.
AU - Husain, Mustafa M.
AU - Maixner, Daniel F.
AU - Riva-Posse, Patricio
AU - McDonald, William M.
N1 - Funding Information:
This work was made possible by a research collaboration supported by the National Network of Depression Centers ( NNDC ), an inter-dependent consortium of academic depression centers and Emory University Fuqua Center for Late-Life Depression.
Funding Information:
APH, FCG, DWL, IMR, AUJ, ZY, LP, YLT, GCG, MMH, DFM, PR have no conflict of interest to declare. SMM has received research support from the National Institutes of Health. He is a consultant to Pearson Assessment.WMM is a paid consultant for Signant Health, grant support from NeoSync and the Stanley Foundation, equipment donated from Neuronetics and Soterix for grants.We thank the participants who kindly took part in the study, and Susan Henderson, NP for administering the tests. The authors acknowledge the assistance of Gisella Klekamp with the graphic design of the ECCA. This work was made possible by a research collaboration supported by the National Network of Depression Centers (NNDC), an inter-dependent consortium of academic depression centers and Emory University Fuqua Center for Late-Life Depression.
Funding Information:
WMM is a paid consultant for Signant Health, grant support from NeoSync and the Stanley Foundation , equipment donated from Neuronetics and Soterix for grants.
Funding Information:
APH, FCG, DWL, IMR, AUJ, ZY, LP, YLT, GCG, MMH, DFM, PR have no conflict of interest to declare. SMM has received research support from the National Institutes of Health . He is a consultant to Pearson Assessment.
Publisher Copyright:
© 2020
PY - 2020/5/15
Y1 - 2020/5/15
N2 - Background: Electroconvulsive therapy (ECT) is a well-established treatment for severe depression but may result in adverse cognitive effects. Available cognitive screening instruments are nonspecific to the cognitive deficits associated with ECT. An ECT-cognitive assessment tool which can be easily administered was developed and validated in a clinical setting. Methods: One hundred and thirty-six participants were enrolled. The ElectroConvulsive therapy Cognitive Assessment (ECCA) and the Montreal Cognitive Assessment (MoCA) were administered prospectively to 55 participants with major depressive disorder (MDD) undergoing ECT at three time points: pre-treatment, before the sixth treatment and one-week post-treatment. The psychometric properties of the total and domain scores were evaluated at all three time points. Forty demographically comparable participants with MDD who did not receive ECT, and 41 healthy, age-matched controls were evaluated at a single time point. Results: ECCA and MoCA scores were not statistically different at baseline. Prior to the sixth and final ECT session, total ECCA scores were significantly lower than the MoCA total scores. The ECCA domains of subjective memory, informant-assessed memory, attention, autobiographical memory and delayed verbal recall were significantly lower post-ECT compared to pre-ECT. Limitations: The ECCA was compared only to the MoCA rather than to a more comprehensive neuropsychological testing. This limitation reflected the real-life clinical burden of performing full neuropsychological testing at three time points during the treatment course. Conclusions: The ECCA is a brief, reliable, bedside cognitive screening assessment tool that may be useful to monitor cognitive function in patients treated with ECT. The test can be downloaded from fuquacenter.org/ecca.
AB - Background: Electroconvulsive therapy (ECT) is a well-established treatment for severe depression but may result in adverse cognitive effects. Available cognitive screening instruments are nonspecific to the cognitive deficits associated with ECT. An ECT-cognitive assessment tool which can be easily administered was developed and validated in a clinical setting. Methods: One hundred and thirty-six participants were enrolled. The ElectroConvulsive therapy Cognitive Assessment (ECCA) and the Montreal Cognitive Assessment (MoCA) were administered prospectively to 55 participants with major depressive disorder (MDD) undergoing ECT at three time points: pre-treatment, before the sixth treatment and one-week post-treatment. The psychometric properties of the total and domain scores were evaluated at all three time points. Forty demographically comparable participants with MDD who did not receive ECT, and 41 healthy, age-matched controls were evaluated at a single time point. Results: ECCA and MoCA scores were not statistically different at baseline. Prior to the sixth and final ECT session, total ECCA scores were significantly lower than the MoCA total scores. The ECCA domains of subjective memory, informant-assessed memory, attention, autobiographical memory and delayed verbal recall were significantly lower post-ECT compared to pre-ECT. Limitations: The ECCA was compared only to the MoCA rather than to a more comprehensive neuropsychological testing. This limitation reflected the real-life clinical burden of performing full neuropsychological testing at three time points during the treatment course. Conclusions: The ECCA is a brief, reliable, bedside cognitive screening assessment tool that may be useful to monitor cognitive function in patients treated with ECT. The test can be downloaded from fuquacenter.org/ecca.
KW - Assessment
KW - Cognitive impairment
KW - Depression
KW - Electroconvulsive Therapy
KW - Memory
UR - http://www.scopus.com/inward/record.url?scp=85081952108&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081952108&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2020.03.010
DO - 10.1016/j.jad.2020.03.010
M3 - Article
C2 - 32217341
AN - SCOPUS:85081952108
SN - 0165-0327
VL - 269
SP - 36
EP - 42
JO - Journal of affective disorders
JF - Journal of affective disorders
ER -